美股異動 | BioNTech漲2% 與英國政府達成合作擬為1萬名患者使用定製癌症藥物
格隆匯1月7日丨BioNTech漲2.31%,報149.03美元,總市值362億美元。英國政府同意與BioNTech(BNTX.US)合作,到2030年用個性化療法治療多達1萬名癌症患者,這一研究合作伙伴關係將BioNTech更快地接觸到測試其藥物所需的患者。知情人士透露,未來8到10年,雙方的合作價值可能高達7.5億美元。英國衞生和社會保障大臣Steve Barclay在一份聲明中表示,英國患者最早將於9月參加該項目。在從與輝瑞公司合作開發的新冠疫苗中獲得數十億美元的銷售額後,BioNTech正將這筆意外之財用於廣泛的實驗藥物管道。該公司正在與競爭對手信使RNA疫苗製造商Moderna競爭,將這一成功用於對抗新冠病毒的平台擴展到癌症治療。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.